All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Microbiome specialist Enterobiotix Ltd. closed a $21.5 million series A to advance development of its live bacteria fecal transplant drug pipeline.
